ATE210148T1 - Neuartige opioid-peptide - Google Patents

Neuartige opioid-peptide

Info

Publication number
ATE210148T1
ATE210148T1 AT96927978T AT96927978T ATE210148T1 AT E210148 T1 ATE210148 T1 AT E210148T1 AT 96927978 T AT96927978 T AT 96927978T AT 96927978 T AT96927978 T AT 96927978T AT E210148 T1 ATE210148 T1 AT E210148T1
Authority
AT
Austria
Prior art keywords
opioid peptides
novel opioid
novel
peptides
opioid
Prior art date
Application number
AT96927978T
Other languages
English (en)
Inventor
Wuyi Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE210148T1 publication Critical patent/ATE210148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96927978T 1995-08-18 1996-08-14 Neuartige opioid-peptide ATE210148T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides
PCT/SE1996/001011 WO1997007130A1 (en) 1995-08-18 1996-08-14 Novel opioid peptides

Publications (1)

Publication Number Publication Date
ATE210148T1 true ATE210148T1 (de) 2001-12-15

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927978T ATE210148T1 (de) 1995-08-18 1996-08-14 Neuartige opioid-peptide

Country Status (27)

Country Link
US (1) US6337319B1 (de)
EP (1) EP0845003B1 (de)
JP (1) JPH11512086A (de)
KR (1) KR19990037677A (de)
CN (1) CN1200127A (de)
AR (1) AR003475A1 (de)
AT (1) ATE210148T1 (de)
AU (1) AU711862B2 (de)
BR (1) BR9610248A (de)
CA (1) CA2229797A1 (de)
CZ (1) CZ287299B6 (de)
DE (1) DE69617699T2 (de)
DK (1) DK0845003T3 (de)
EE (1) EE9800048A (de)
ES (1) ES2171224T3 (de)
HU (1) HUP9901209A3 (de)
IL (1) IL123258A (de)
IS (1) IS4664A (de)
NO (1) NO980592D0 (de)
NZ (1) NZ315809A (de)
PL (1) PL325113A1 (de)
RU (1) RU2165432C2 (de)
SE (1) SE9503924D0 (de)
SK (1) SK282469B6 (de)
TR (1) TR199800258T1 (de)
TW (1) TW424095B (de)
WO (1) WO1997007130A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7825231B2 (en) * 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (de) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptide und deren Verwendung
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
JP5244810B2 (ja) 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) * 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de) 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
CZ168194A3 (en) * 1992-11-12 1994-12-15 Biomeasure Opioid peptides
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
CZ40198A3 (cs) 1998-08-12
NO980592L (no) 1998-02-11
DE69617699T2 (de) 2003-08-07
EP0845003A1 (de) 1998-06-03
NO980592D0 (no) 1998-02-11
IS4664A (is) 1998-02-04
SK282469B6 (sk) 2002-02-05
PL325113A1 (en) 1998-07-06
WO1997007130A1 (en) 1997-02-27
DK0845003T3 (da) 2002-07-15
IL123258A (en) 2003-03-12
ES2171224T3 (es) 2002-09-01
CZ287299B6 (en) 2000-10-11
CN1200127A (zh) 1998-11-25
BR9610248A (pt) 1999-07-06
CA2229797A1 (en) 1997-02-27
EE9800048A (et) 1998-08-17
KR19990037677A (ko) 1999-05-25
AU6760096A (en) 1997-03-12
SE9503924D0 (sv) 1995-11-07
EP0845003B1 (de) 2001-12-05
HUP9901209A3 (en) 2000-12-28
JPH11512086A (ja) 1999-10-19
NZ315809A (en) 1999-05-28
TR199800258T1 (xx) 1998-05-21
AU711862B2 (en) 1999-10-21
DE69617699D1 (de) 2002-01-17
IL123258A0 (en) 1998-09-24
RU2165432C2 (ru) 2001-04-20
TW424095B (en) 2001-03-01
US6337319B1 (en) 2002-01-08
SK20398A3 (en) 1998-12-02
AR003475A1 (es) 1998-08-05
HUP9901209A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
DK0845003T3 (da) Hidtil ukendte opioid-peptider
EP0853483A4 (de) Neue peptide
FI973162A0 (fi) Liikalihavuutta vastustavia proteiineja
FI961350L (fi) Hapteenimerkityt peptidit
DK0739831T3 (da) Transportør
FI965225A7 (fi) Uusia peptidejä
DK0768252T3 (da) Transportør
DE69620006D1 (de) Sequenzierverfahren
NO985680D0 (no) Peptidderivater
FI953302L (fi) Uudet peptidit
NO976058L (no) Rekombinant mistellectin
FI940109L (fi) Peptidejä
NO983849L (no) Peptidderivater
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
FI970168A7 (fi) Peptidejä
BR9609671A (pt) Amino uracilas substituídas
FI964363L (fi) Peptidejä
EE9600208A (et) Uued immuunomodulatoorse toimega peptiidid
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
BR9510586A (pt) Inflador
FR2732345B1 (fr) Peptide antibacterien
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties